|
|
Article: Sepracor Inc. and GlaxoSmithKline Announce International Alliance for Commercialization of LUNIVIA(R) (LUNESTA(R) in U.S.).
- Article from:
- Business Wire
- Article date:
- September 11, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
* Sepracor to Receive Licensing and Milestone Payments from GSK of up to $155 Million
* Marketing Authorization Application (MAA) for LUNIVIA brand eszopiclone is under European Medicines Agency (EMEA) review
* European Union (EU) Approval Targeted for Second Half of 2008
* European Insomnia Market Estimated at Approximately $500 Million in 2006
MARLBOROUGH, Mass. & LONDON -- Sepracor Inc. (Nasdaq: SEPR) and GlaxoSmithKline (GSK) today announced an agreement for the commercialization of Sepracor's eszopiclone product for all markets worldwide (excluding the U.S., Canada, Mexico and Japan). Sepracor's eszopiclone product will be ...